Researchers at the University of Washington have identified a currently FDA-approved drug that could enhance the efficacy of immunotherapy against fibrolamellar carcinoma, a rare type of liver cancer that has historically been unresponsive to checkpoint inhibitors. The discovery offers new hope for patients with this difficult-to-treat cancer and may have implications for other malignancies.
Fibrolamellar carcinoma primarily affects adolescents and young adults, and standard immunotherapies have shown limited success due to the tumor's unique biology. The University of Washington team found that the approved drug, when combined with checkpoint inhibitors, significantly improved immune response in preclinical models. While the study focused on fibrolamellar carcinoma, the findings could extend to other cancers that evade immune detection.
This research comes amid growing interest in combination therapies to overcome resistance to checkpoint inhibitors. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) are also pursuing innovative approaches to enhance immunotherapy outcomes. The news underscores the potential of repurposing existing drugs to expand treatment options.
The study's results were published in a peer-reviewed journal, and further clinical trials are needed to confirm efficacy in humans. If successful, this approach could provide a cost-effective strategy to improve outcomes for patients with fibrolamellar carcinoma and potentially other cancers.
For more information, visit BioMedWire.
